EGFR-IN-213 是 EGFRL858R/T790M/C797S 的选择性抑制剂,对人源靶点的 IC50 为 0.48 nM,可作为抗增殖剂诱导细胞凋亡与细胞周期阻滞,并抑制集落形成、细胞迁移及管形成,可用于非小细胞肺癌、慢性粒细胞白血病、胃癌和前列腺癌的相关研究。
产品编号: MS-G29236 CAS No.: 3115216-45-7 分子式: C35H43Cl3N9O2P 分子量: 759.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

EGFR-IN-213 是 EGFRL858R/T790M/C797S 的选择性抑制剂,对人源靶点的 IC50 为 0.48 nM,可作为抗增殖剂诱导细胞凋亡与细胞周期阻滞,并抑制集落形成、细胞迁移及管形成,可用于非小细胞肺癌、慢性粒细胞白血病、胃癌和前列腺癌的相关研究。

生物实验数据

生物活性 EGFR-IN-213 is a selective inhibitor of EGFRL858R/T790M/C797S with an IC50 of 0.48 nM against the human target, and it acts as an antiproliferative agent by inducing apoptosis and cell cycle arrest while inhibiting colony formation, cell migration, and tube formation, making it useful for research on non-small cell lung cancer, chronic myeloid leukemia, gastric cancer, and prostate cancer.
IC50 & Target

EGFRL858R/T790M/C797S

0.48 nM (IC50)

Akt

 

PI3K

 

体外研究
(In Vitro)

EGFR-IN-213 (化合物 8c) (1 h) 可强效且选择性地抑制 EGFRL858R/T790M/C797S 激酶,其 IC50 为 0.48 nM。
EGFR-IN-213 (72 h) 可强效抑制 BaF3-EGFRL858R/T790M/C797S 细胞 (IC50 = 0.249 μM) 和 H1975 细胞 (IC50 = 0.082 μM) 的增殖,同时对非靶标癌细胞系的活性降低,且对 HEK-293T 细胞的毒性可忽略不计。
EGFR-IN-213 (0.3-1 μM; 24 h) 可浓度依赖性地将 BaF3-EGFRL858R/T790M/C797S 细胞阻滞于 G1 期,在 0.3 μM 和 1 μM 浓度下的活性强于 Brigatinib (MS-T97165)。
EGFR-IN-213 (1-9 μM; 48 h) 可浓度依赖性地诱导 BaF3-EGFRL858R/T790M/C797S 细胞发生凋亡,且在 1 μM、3 μM 和 9 μM 浓度下的活性比 Brigatinib 更强。
EGFR-IN-213 (0.3-3 μM; 48 h) 可浓度依赖性地诱导 H1975 细胞发生凋亡形态学改变。
EGFR-IN-213 (1-3 μM (BaF3-EGFRL858R/T790M/C797S cells); 0.3-1 μM (H1975 cells); 24 h) 可浓度依赖性地抑制 BaF3-EGFRL858R/T790M/C797S 细胞中 EGFR 的磷酸化,并抑制 H1975 细胞中 EGFR、PI3K 和 AKT 的磷酸化,其效力和选择性均优于 Brigatinib。
EGFR-IN-213 (1-3 μM; 24 h) 可浓度依赖性地抑制 H1975 细胞的集落形成。
EGFR-IN-213 (0.1-1 μM (Transwell migration); 1 μM (wound healing); 24 h (Transwell migration); 48 h (wound healing)) 可在 Transwell 迁移实验和划痕愈合实验中呈剂量依赖性抑制 H1975 细胞的迁移能力。
EGFR-IN-213 (0.3-3 μM; 48 h) 可浓度依赖性地抑制 HUVECs 的管形成,展现出抗血管生成活性。

Cell Cycle Analysis

Cell Line: BaF3-EGFR(L858R/T790 M/C797S) cells
Concentration: 0.3, 1 μM
Incubation Time: 24 h
Result: Induced G1 phase arrest in 83.43% of BaF3-EGFR(L858R/T790 M/C797S) cells at 0.3 μM.
Induced G1 phase arrest in 88.97% of BaF3-EGFR(L858R/T790 M/C797S) cells at 1 μM.
Showed superior activity compared to brigatinib at equivalent concentrations.

Apoptosis Analysis

Cell Line: BaF3-EGFR(L858R/T790 M/C797S) cells
Concentration: 1, 3, 9 μM
Incubation Time: 48 h
Result: Induced apoptosis in 79.54% of BaF3-EGFR(L858R/T790 M/C797S) cells at 1 μM.
Induced apoptosis in 89.60% of BaF3-EGFR(L858R/T790 M/C797S) cells at 3 μM.
Induced apoptosis in 97.08% of BaF3-EGFR(L858R/T790 M/C797S) cells at 9 μM.
Showed greater pro-apoptotic activity than brigatinib at equivalent concentrations.

Apoptosis Analysis

Cell Line: H1975 cells
Concentration: 0.3, 1, 3 μM
Incubation Time: 48 h
Result: Induced apoptotic morphological changes including yellow-green (early apoptosis) and orange-red (late apoptosis) fluorescence with AO/EB staining in a concentration-dependent manner.
Induced nuclear shrinkage, fragmentation, and enhanced fluorescence intensity with Hoechst33342 staining in a concentration-dependent manner.

Western Blot Analysis

Cell Line: BaF3-EGFR(L858R/T790 M/C797S) and H1975 cells
Concentration: 1, 3 μM (BaF3-EGFR(L858R/T790 M/C797S) cells); 0.3, 1 μM (H1975 cells)
Incubation Time: 24 h
Result: Concentration-dependently suppressed EGFR phosphorylation in BaF3-EGFR(L858R/T790 M/C797S) cells, with greater potency than brigatinib.
Dose-dependently suppressed phosphorylation of EGFR, PI3K, and AKT in H1975 cells, with greater selectivity for EGFR phosphorylation inhibition than brigatinib.

Cell Proliferation Assay

Cell Line: H1975 cells
Concentration: 1, 3 μM
Incubation Time: 24 h
Result: Decreased the number of H1975 cell colonies in a concentration-dependent manner, with fewer colonies observed at higher concentrations.

Cell Invasion Assay

Cell Line: H1975 cells
Concentration: 0.1, 0.3, 1 μM (Transwell migration); 1 μM (wound healing)
Incubation Time: 24 h (Transwell migration); 24, 48 h (wound healing)
Result: Dose-dependently reduced the number of migrated H1975 cells in the Transwell assay, with similar inhibitory effect to brigatinib.
Markedly impeded wound closure in the wound healing assay at 1 μM compared to the control group, with similar activity to brigatinib.

化学信息

分子量 759.11
分子式 C35H43Cl3N9O2P
CAS No. 3115216-45-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础